Pliant Therapeutics Inc

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for the treatment of solid tumors. Its lead product candidate, PLN-101095, is an oral small molecule dual inhibitor of avß8 and avß1 integrins currently in Phase 1a/1b trials for solid tumors. The company is also developing a drug discovery platform that includes a proprietary library of over 15,000 integrin binding molecules, with a focus on integrin-based target-mediated drug delivery. Incorporated in 2015, Pliant Therapeutics is headquartered in South San Francisco, California.